Treats tissue inside the body using a single probe that fires microwave and radiofrequency energy at the same time, controlled by software that prevents burning.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- Scale
Treats tissue inside the body using a single probe that fires microwave and radiofrequency energy at the same time, controlled by software that prevents burning.
What this company is and how it runs — written from structure, not news.
Creo Medical Group builds a single endoscopic catheter that fires microwave and radiofrequency energy at the same time, cutting and sealing tissue in one pass rather than two separate procedures. Because the two energy types penetrate tissue at different depths, their combined effect shifts continuously with the electrical state of the tissue being treated, so proprietary algorithms read that live feedback and adjust each energy output in real time to prevent charring — without those algorithms running, the catheter becomes an uncontrolled two-modality device and the clinical case for using it disappears. Every generator sold into an endoscopy suite embeds that calibration logic, and once a hospital has bought a generator, its surgeons must train on dual-energy techniques, its facilities must pass new electromagnetic compatibility assessments, and its electrical isolation systems must be upgraded — all of which makes switching to a competitor an infrastructure project rather than a purchasing decision. The one thing that caps how fast the business can grow is that every manufacturing batch of catheters and generators must be tested individually for electromagnetic interference between the two circuits, because component tolerances shift the interaction point in ways that cannot be standardized, and only a handful of specialist facilities can run that verification at surgical-grade precision.
How does this company make money?
The company sells disposable endoscopic catheters, one per procedure, which creates revenue that grows with procedure volumes. It also sells the generator units that run the control algorithms. Each generator sale ties an endoscopy suite to the company's calibration system, which in turn drives continued purchases of the disposable catheters that only work with that generator.
What makes this company hard to replace?
Surgeons must complete training specifically for dual-energy tissue interaction techniques, which differ meaningfully from standard radiofrequency-only procedures. Hospitals must complete new electromagnetic compatibility assessments before a dual-energy device can be used in a suite. Endoscopy suites also need updated electrical isolation systems to safely handle simultaneous microwave and radiofrequency outputs, which adds procurement and installation work before any switch could happen.
What limits this company?
Every manufacturing batch must be individually tested for electromagnetic interference between the microwave and radiofrequency circuits, because small differences in components shift the point where the two energy sources interact. That testing requires specialized facilities capable of running dual-energy checks at surgical-grade precision, and the capacity of those facilities sets a hard ceiling on how many units can be produced.
What does this company depend on?
The company cannot operate without CE marking approval to sell active medical devices in Europe, microwave generator components from RF semiconductor suppliers, radiofrequency ablation chips, endoscopic catheter materials that meet ISO 10993 biocompatibility standards, and electromagnetic compatibility testing facilities capable of verifying dual-energy devices.
Who depends on this company?
Gastroenterologists performing endoscopic submucosal dissection would lose the ability to cut and coagulate in a single pass and would have to swap instruments mid-procedure. Pulmonologists doing bronchoscopic ablations would need to run sequential procedures with separate energy sources instead of finishing in one pass. Endoscopy centers would face longer procedure times and higher costs from carrying more instruments.
How does this company scale?
Once the energy-modulation algorithms are validated, they can be loaded onto an unlimited number of generator units at almost no added cost. What does not scale easily is production volume, because every manufacturing batch of catheters and generators still requires individual electromagnetic interference testing that cannot be skipped or standardized away.
What external forces can significantly affect this company?
Brexit trade arrangements create uncertainty around regulatory pathways between the company's Wales-based manufacturing and EU market access. NHS capital equipment budget constraints limit how quickly UK hospitals can purchase new generator units. Regulatory changes requiring additional clinical evidence for combination energy devices could delay or block new product approvals.
Where is this company structurally vulnerable?
If the small group of electromagnetic engineers and algorithm developers who maintain the dual-energy control software left and could not be replaced, no amount of hardware investment would restore the system. The control logic depends on specialized knowledge of tissue interaction physics that is not fully documented in a transferable form and is not available from any external software vendor.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph